Takeda Pharmaceutical Company Limited Total Assets
Takeda Pharmaceutical Company Limited total assets. Based on the latest financial reports, Takeda Pharmaceutical Company Limited (TKDA) holds total assets worth €15.41 Trillion EUR (≈ $18.01 Trillion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TKDA cash generation efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Takeda Pharmaceutical Company Limited (2017–2025)
Total assets of Takeda Pharmaceutical Company Limited from 2017 to 2025. This chart illustrates how Takeda Pharmaceutical Company Limited's total assets have evolved over time, based on quarterly financial data. See latest Takeda Pharmaceutical Company Limited stock price today for real-time trading data and today's change.
Takeda Pharmaceutical Company Limited - Asset Composition Analysis
Takeda Pharmaceutical Company Limited Total Assets Breakdown (March 2025)
Takeda Pharmaceutical Company Limited total assets breakdown as of March 2025. Takeda Pharmaceutical Company Limited's total assets of €15.41 Trillion consist of 17.7% current assets and 82.3% non-current assets. Explore TKDA net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.7% |
| Accounts Receivable | €770.90 Billion | 5.4% |
| Inventory | €1.22 Trillion | 8.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.63 Trillion | 25.5% |
| Goodwill | €5.32 Trillion | 37.4% |
Asset Composition Trend (2017–2025)
This chart illustrates how Takeda Pharmaceutical Company Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Takeda Pharmaceutical Company Limited's current assets represent 17.7% of total assets in 2025, a decrease from 28.9% in 2017.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2025, down from 7.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 47.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 37.4% of total assets.
Takeda Pharmaceutical Company Limited Competitors by Total Assets
Key competitors of Takeda Pharmaceutical Company Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Abbott India Limited
NSE:ABBOTINDIA
|
India | Rs56.94 Billion |
|
Shenzhen Salubris Pharmaceuticals Co Ltd
SHE:002294
|
China | CN¥10.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Shanxi Zhendong Pharmaceutical
SHE:300158
|
China | CN¥4.51 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Aprogen Pharmaceuticals Inc
KO:003060
|
Korea | ₩603.42 Billion |
Takeda Pharmaceutical Company Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.31 | 1.53 |
| Quick Ratio | 0.65 | 0.72 | 1.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €506.26 Billion | €656.32 Billion | €939.72 Billion |
Takeda Pharmaceutical Company Limited - Advanced Valuation Insights
This section examines the relationship between Takeda Pharmaceutical Company Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.06 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | €14.25 Trillion |
| Market Capitalization | $43.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Takeda Pharmaceutical Company Limited's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Takeda Pharmaceutical Company Limited's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Takeda Pharmaceutical Company Limited (2017–2025)
The table below shows the annual total assets of Takeda Pharmaceutical Company Limited from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €14.25 Trillion ≈ $16.66 Trillion |
-5.70% |
| 2024-03-31 | €15.11 Trillion ≈ $17.66 Trillion |
+8.25% |
| 2023-03-31 | €13.96 Trillion ≈ $16.32 Trillion |
+5.92% |
| 2022-03-31 | €13.18 Trillion ≈ $15.41 Trillion |
+2.06% |
| 2021-03-31 | €12.91 Trillion ≈ $15.10 Trillion |
+0.71% |
| 2020-03-31 | €12.82 Trillion ≈ $14.99 Trillion |
-7.58% |
| 2019-03-31 | €13.87 Trillion ≈ $16.22 Trillion |
+237.82% |
| 2018-03-31 | €4.11 Trillion ≈ $4.80 Trillion |
-5.72% |
| 2017-03-31 | €4.36 Trillion ≈ $5.09 Trillion |
-- |
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more